LIFE SCIENCES TOOLS & SERVICES INDUSTRY

exiqon a/s (EXQ:Copenhagen)

Last kr8.80 DKK

Change Today 0.00 / 0.00%

Volume 6.7K

EXQ On Other Exchanges

Symbol

Exchange

EXQNF:US

OTC US

EXQ:DC

Copenhagen

As of 11:04 AM 05/22/13 All times are local (Market data is delayed by at least 15 minutes).

exiqon a/s (EXQ) Snapshot

Open kr8.80		Previous Close kr8.80
Day High kr8.90		Day Low kr8.80
52 Week High 06/11/12 - kr10.50		52 Week Low 02/6/13 - kr7.35
Market Cap 324.5M		Average Volume 10 Days 16.3K
EPS TTM kr-0.29		Shares Outstanding 36.9M
EX-Date --		P/E TM --
Dividend --		Dividend Yield --

Current Stock Chart for EXIQON A/S (EXQ)

EXQ:DC Historical Stock Quote
EXQ:DC Advanced Stock Chart

Related News

No related news articles were found.

exiqon a/s (EXQ) Related Businessweek News

No Related Businessweek News Found

exiqon a/s (EXQ) Details

Exiqon A/S provides products for microRNA research worldwide. The company’s products serve as a platform for the development of molecular diagnostic tests. It develops molecular diagnostic tests in collaboration with pharmaceutical and diagnostic companies. The company’s products include RNA isolation kits; microRNA Array system, a system for global microRNA expression profiling; microRNA qPCR system, which enables microRNA expression profiling; microRNA detection probes that are used for the ultra-sensitive and detection of microRNAs by Northern blot analysis; and microRNA inhibitor products for functional analysis of microRNAs. It also offers RNA microarrays that capture probes for expression analysis of splice variants, small RNAs, and even mRNA; qPCR assays for mRNA and ncRNA; RNA detection probes for in situ hybridization and Northern blot; longRNA GapmeR, which are antisense oligonucleotides used for the inhibition of mRNA and lncRNA function; SNP (single nucleotide polymorphism) detection oligonucleotides; SNP microarrays; FISH probes; custom LNA oligonucleotides; LNA phosphoramidites for the synthesis of LNA containing oligonucleotides; and A2-quencher phosphoramidite, a dark quencher with no native fluorescence developed for real-time PCR probes. In addition, the company provides RNA isolation services for the sample types, including blood derived serum, plasma and other bio-fluids, clinical FFPE and fresh frozen tissues, and cell lines; MicroRNA array services; MicroRNA profiling services; and in situ hybridization screening services. Exiqon A/S sells its products primarily under the miRCURY, miRCURY LNA, and LNA brands. The company markets its research products through direct sales, distributors, and the Web. Exiqon A/S was founded in 1995 and is headquartered in Vedbaek, Denmark.

Detailed EXQ:DC Company Description...

www.exiqon.com

76 Employees
Last Reported Date: 05/6/13

Founded in 1995

exiqon a/s (EXQ) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

exiqon a/s (EXQ) Key Developments

Exiqon A/S Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2013; Provides Earnings Guidance for the Full Year 2013

May 7 13

Exiqon A/S reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported revenue of DKK 31,765,000, LBIT of DKK 3,369,000, loss before tax of DKK 4,325,000, loss of DKK 4,470,000 or DKK 0.12 per diluted share against revenue of DKK 23,968,000, LBIT of DKK 6,798,000, loss before tax of DKK 8,144,000, loss of DKK 8,235,000 or DKK 0.21 per diluted share a year ago. Cash used in operating activities was DKK 3,189,000 against DKK 210,000 a year ago. Acquisition of property, plant and equipment was DKK 119,000 against DKK 288,000 a year ago. Acquisition of intangible assets was DKK 167,000 against DKK 221,000 a year ago. LBITDA was DKK 2,045,000 compared to DKK 4,802,000 a year ago. In 2013 the company expects total revenue of approximately DKK 130 million which reflects an expectation of double digit growth and a positive result measured on EBITDA. The company expects cash flow from operating activities to be positive in 2013.

Exiqon A/S Reports Parent Earnings Results for the Full Year Ended December 31, 2012

Mar 12 13

Exiqon A/S reported parent earnings results for the full year ended December 31, 2012. For the period the company reported revenue of DKK 97,071,000, LBIT of DKK 13,120,000, loss before tax of DKK 14,057,000, loss of DKK 12,807,000 against revenue of DKK 93,340,000, LBIT of DKK 22,316,000, loss before tax of DKK 25,742,000, loss of DKK 25,742,000. Cash used in operating activities was DKK 3,464,000 against DKK 30,117,000 a year ago. Acquisition of property, plant and equipment was DKK 354,000 against DKK 512,000 a year ago. Acquisition of intangible assets was DKK 1,109,000 against DKK 1,586,000 a year ago.

Exiqon A/S Reports Consolidated and Unconsolidated Earnings Results for the Full Year Ended December 31, 2012; Provides Earnings Guidance for Fiscal 2013

Feb 7 13

Exiqon A/S reported consolidated and unconsolidated earnings results for the full year ended December 31, 2012. On consolidated basis, the company reported revenue of DKK 117,400,000, LBIT of DKK 11,777,000, loss before tax of DKK 13,665,000, loss of DKK 14,595,000 or DKK 0.41 per diluted share against revenue of DKK 111,458,000, LBIT of DKK 28,470,000, loss before tax of DKK 29,262,000, loss of DKK 24,894,000 or DKK 0.71 per diluted share a year ago. Cash used in operating activities was DKK 5,679,000 against DKK 27,345,000 a year ago. Acquisition of property, plant and equipment was DKK 495,000 against DKK 512,000 a year ago. Acquisition of intangible assets was DKK 1,109,000 against DKK 1,586,000 a year ago. Revenue increased 5% to DKK 117.4 million (DKK 111.5 million), driven primarily by a 11% increase in sales of the company's own proprietary life sciences products and services (excluding OEM) to DKK 90.7 million (81.8 million). On unconsolidated basis, the company reported revenue of DKK 53,321,000, LBIT of DKK 13,120,000, loss before tax of DKK 14,057,000, loss of DKK 12,807,000 against revenue of DKK 93,340,000, LBIT of DKK 22,316,000, loss before tax of DKK 25,742,000, loss of DKK 25,742,000 a year ago. Cash used in operating activities was DKK 3,464,000 against DKK 30,117,000 a year ago. Acquisition of property, plant and equipment was DKK 354,000 against DKK 512,000 a year ago. Acquisition of intangible assets was DKK 1,109,000 against DKK 1,586,000 a year ago. In 2013, the company expects total revenue of approximately DKK 130 million which reflects an expectation of double digit growth and a positive result measured on EBITDA. The company expects cash flow from operating activities to be positive in 2013.